Announcement of TTY Biopharm's unaudited income information in September 2025
2025.10.14
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/10/14 | Time of announcement | 18:03:11 |
| Subject | Announcement of TTY Biopharm's unaudited income information in September 2025 | ||||
| Date of events | 2025/10/14 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2025/10/14 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $879,494 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $296,361 thousands, and a consolidated income before tax of $593,809 thousands in September 2025; net income attributed to stockholders of the company was $457,218 thousands; EPS is $1.84. Year-to-date consolidated net sales was $4,790,870 thousands (in NT dollars; unaudited), a consolidated operating profit was $1,346,476 thousands and consolidated income before tax was $1,790,114 thousands until September 2025; year-to-date net income attributed to stockholders of the company was $1,344,915 thousands; EPS is $5.41. 6.Countermeasures:None. 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): (1)The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. (2)The out-of-court settlement between TTY and Inopha AG (Switzerland) and its material beneficiary, Mr. Denis Opitz, revenue has been fully recognized as of this month. |
||||